Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.

Abstract excerpt

INTRODUCTION: Cholangiocarcinoma (CCA) is an uncommon malignancy originating from epithelial cells of the biliary tract. Regardless of the site of origin within the biliary tree, CCAs are generally aggressive with a poor survival. Surgical resection remains the only chance for cure, yet a majority of patients are not surgical candidates at presentation. Unfortunately, systemic therapies are often ineffective and...

Topics

Join the communities discussing this publication.

• Bile Ducts, Intrahepatic
• Cholangiocarcinoma
• Bile Duct Neoplasms
• Isocitrate Dehydrogenase
• Molecular Targeted Therapy